Andrew M. Tonkin

Mar 29, 2024 | digitalcommons.library.tmc.edu | John McNeil |John Mcneil |Rory Wolfe |Robyn L. Woods |Andrew M. Tonkin

BACKGROUND: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.

Nov 27, 2023 | n.neurology.org | Zhen Zhou |Joanne Ryan |Andrew M. Tonkin

Glossary3MS=Modified Mini-Mental State Examination; AD=Alzheimer disease; ASPREE=Aspirin in Reducing Events in the Elderly; ASPREE-XT=ASPREE-eXTension; CVD=cardiovascular disease; HDL-c=high-density lipoprotein cholesterol; HR=hazard ratio; IQR=interquartile range; LDL-c=low-density lipoprotein cholesterol; PUTG=polyunsaturated fatty acid containing triglycerideFootnotesGo to Neurology.org/N for full disclosures.

Nov 8, 2023 | nature.com | Andrew M. Tonkin

AbstractLipoprotein(a) (Lp(a)) is associated with atherothrombosis through several mechanisms, including putative antifibrinolytic properties. However, genetic association studies have not demonstrated an association between high plasma levels of Lp(a) and the risk of venous thromboembolism, and studies in patients with highly elevated Lp(a) levels have shown that Lp(a) lowering does not modify the clotting properties of plasma ex vivo.

Oct 25, 2023 | n.neurology.org | Zhen Zhou |Joanne Ryan |Andrew M. Tonkin |Sophia Zoungas

Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study Zhen Zhou, Joanne Ryan, Andrew M Tonkin, Sophia Zoungas, Paul Lacaze, Rory Wolfe, Suzanne G Orchard, Anne M Murray, John J Mcneil, Chenglong Yu, Gerald F Watts, Sultana Monira Hussain, Lawrence J Beilin, Michael Ernst, Nigel Stocks, Robyn L Woods, Chao Zhu, Christopher Reid, Raj C Shah, Trevor T Chong, Ajay Sood, Kerry M Sheets, Mark Nelson Neurology Oct 2023,...

Mar 13, 2023 | amjmed.com | Zhen Zhou |Wei Zhang |David P Burgner |Andrew M. Tonkin

To determine the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use on incident sepsis and other severe infections. We searched PubMed, EMBASE, CENTRAL and ClinicalTrial.gov up to September 14, 2021 for double-blind, placebo-controlled randomized trials of alirocumab, evolocumab, or inclisiran with >100 participants in each arm and report of serious adverse events related to infection.